TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Sahajanand Medical Technologies (SMT) Hydra TAVR

Hydra TAVR valve gains key approval as global reach continues to grow

The self-expanding device is now available in more than 20 countries and received CE mark approval back in 2020. However, it has not yet been approved by the U.S. Food and Drug Administration for use in the United States.

Heart cardiologists doctors surgery

SAVR outperforms TAVR in patients with bicuspid aortic valves

BAV patients are often excluded from TAVR trials, creating uncertainty about the best way to treat that population when aortic valve replacement is required. To learn more, researchers tracked CMS data from 2018 to 2022, presenting their findings in The Annals of Thoracic Surgery.

A TAVR procedure being performed at Northwestern Medicine in Chicago. These structural heart procedures require a team approach.

Treating AFib patients with TAVR still linked to elevated risks

While the technology and techniques associated with TAVR have advanced over the years, treating patients who present with baseline atrial fibrillation is still associated with certain risks.

Sapien 3 Ultra Resilia TAVR valves

Years of progress have made TAVR more effective when treating concomitant mitral stenosis

Newer balloon-expandable TAVR valves are associated with much better outcomes for patients presenting with both severe AS and severe MS than older models.

Cardiologist heart

TAVR/PCI bests SAVR/CABG when treating severe AS and complex CAD

Percutaneous treatment was linked to improved survival and fewer adverse events than surgery when patients presented with both symptomatic severe aortic stenosis and complex coronary artery disease. 

Thumbnail

TAVR survival less likely when patients are depressed

Screening TAVR patients for signs of depression prior to treatment could help providers adapt as necessary and deliver better patient care.

Robotic aortic valve replacement (RAVR) is a new minimally invasive treatment option for symptomatic severe aortic stenosis (AS) that uses advanced robotic surgical systems. It has already started gaining momentum as an alternative to both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).

Q&A: Pioneer heart surgeon on the development and long-term potential of robotic aortic valve replacement

It's early for RAVR, but the minimally invasive technique has already started gaining momentum as an alternative to both SAVR and TAVR. We spoke to Vinay Badhwar, MD, one of the world’s leading voices in robotic heart surgery, to learn more.

Off-label TAVR for native aortic regurgitation linked to worse outcomes

Targeting aortic regurgitation with TAVR valves built to treat aortic stenosis may be the only option a cardiologist has—but valves designed specifically to treat AR are linked to much better outcomes, according to a new meta-analysis. Edwards Lifesciences recently acquired the two companies at the center of this study, JenaValve and JC Medical.

Displaying 1 - 8 of 419
Design by Adaptive Theme